Recruiting
NCT06415175
Atopic Dermatitis
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
+ 6 month(s) and - 11 year(s)
Study targets participants aged from 6 month(s) to 11 year(s)
All gender
This study targets all gender participants
N/A
general.n_aDetailText
150 participants
Study involves a large group of participants
15 locations
Available in numerous locations
Study Overview
This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease characteristics, prior treatments for and treatment prescription modalities. As well as to document the real-world effectiveness and safety of dupilumab during the two years of follow up. No diagnostic or therapeutic intervention outside of routine clinical practice will be applied.
Eligibility Criteria
Inclusion Criteria:
- Male or female aged 6 months to 11 years old at baseline.
- Patients with severe Atopic dermatitis (AD) according to the investigator's assessment.
- Patients initiating dupilumab (in those patients initiated retrospectively 2 months before the start of the study, the baseline information must be correctly filled out in the medical records).
- Signed informed consent by the parent/legally acceptable representative and assent by the patient appropriate to the patient's age.
Exclusion Criteria:
- Patients who are participating in an interventional clinical trial that modifies patient care.